SOMAÍ Pharmaceuticals has officially joined forces with Pacific Cannovation Company Limited (PACCAN) to elevate Thailand as a global leader in high-quality medicinal cannabis. This collaboration marks a significant milestone in the cannabis industry, combining SOMAÍ’s extensive global distribution capabilities with PACCAN’s local expertise in Thailand, setting the stage for a powerful cross-continental partnership.
As Thailand rapidly emerges as Asia’s fastest-growing medicinal cannabis market—projected to reach $1 billion in sales by 2024—this partnership aims to place Thai cannabis on the world map. SOMAÍ leverages its experience in navigating complex regulatory environments, ensuring that only EU-GMP certified products reach patients in Europe, the UK, and beyond. Meanwhile, PACCAN stands as a trailblazer in plant-based biotechnology, showcasing Thailand’s commitment to responsible and ethical cannabis production at the highest medical standards.
A Cross-Continental Powerhouse
This collaboration reinforces Thailand’s position as Asia’s cannabis epicenter while seamlessly integrating its products into SOMAÍ’s expansive distribution network, which spans 12 countries and continues to grow.
- Exclusive Representation: SOMAÍ will exclusively represent PACCAN in Europe and the Rest of the World (ROW).
- Future Developments: The partnership includes distribution agreements for medicinal cannabis flowers, extracts, and plans for future product innovation and clinical trials.
By utilizing SOMAÍ’s unmatched quality assurance, regulatory compliance, and inventory management capabilities, this alliance ensures that patients globally receive only the highest-quality products. To fortify their partnership, SOMAÍ will assist PACCAN in achieving EU-GMP certification for its state-of-the-art facilities, creating a collaborative framework that maximizes their combined strengths.
“Our partnership aims to set a new standard in global collaborations where two unique companies from different continents can leverage each other’s expertise,” stated Michael Sassano, CEO of SOMAÍ Pharmaceuticals. “This collaboration shows that Thai medicinal cannabis can compete with the best in the world, ensuring that European products thrive in Asia. It’s not just about business; it’s about shared vision and improved patient outcomes.”
Joe Trairatanobhas, CEO of PACCAN, remarked, “Partnering with SOMAÍ is a significant leap for us into the global medical cannabis marketplace. Their established distribution network will synergize perfectly with PACCAN’s strong presence in Asia, creating an efficient platform for patients to access premium-quality products at competitive prices. Asia will undoubtedly become one of the largest markets for medical cannabis, especially with its aging population. I believe this partnership will lead to innovative products across the herbal medicine spectrum.”
Suppachai Jaisamut, Advisor to the Minister of Interior and former Chairman of the National Cannabis Committee, emphasized the importance of this partnership. “PACCAN has been a leader in Thailand’s medical cannabis sector. With SOMAÍ, the door is now open for legally produced, high-quality Thai cannabis to enter international markets. Under Michael Sassano’s guidance, the Thai medical cannabis industry finally has its chance to shine on the global stage.”
The Future of Medicinal Cannabis
Looking ahead, as Thailand gears up to implement its irreversible Cannabis Act by March 2025, the nation is set to become a nexus for plant-based medicines across Asia. SOMAÍ and PACCAN are strategically positioned to spearhead this movement by merging innovation with ethical practices to enhance the entire industry.
With this groundbreaking partnership, SOMAÍ and PACCAN are set to pave the way for a global cannabis network, establishing strong links between Asia and Europe through shared expertise, innovation, and unwavering commitment to excellence.
